Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083767 | 0.90 | IGF1R (0.46) | IGF1RCYP3A4TNK2NPC1RAB9A | |
| SCHEMBL5080265 | 0.89 | RAB9A (0.35) | IGF1RCYP3A4TNK2NPC1RAB9A | |
| SCHEMBL5083969 | 0.88 | IGF1R (0.46) | IGF1RCYP3A4TNK2 | |
| SCHEMBL5081269 | 0.87 | CYP3A4 (0.39) | IGF1RCYP3A4TNK2 | |
| SCHEMBL5085063 | 0.82 | IGF1R (0.42) | IGF1RCYP3A4TNK2 | |
| SCHEMBL5085497 | 0.81 | TNK2 (0.44) | IGF1RCYP3A4TNK2MCHR1 | |
| SCHEMBL5258044 | 0.79 | IGF1R (0.58) | IGF1RCYP3A4TNK2FLT3 | |
| SCHEMBL5084929 | 0.78 | IGF1R (0.47) | IGF1RCYP3A4TNK2NPC1RAB9A | |
| SCHEMBL5083550 | 0.77 | IGF1R (0.40) | IGF1RCYP3A4TNK2NPC1RAB9A | |
| SCHEMBL399308 | 0.76 | IGF1R (0.67) | IGF1RCYP3A4TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979002-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |